- Status Complete
- Type New application
- Pre-PASC consultation -
- Pre-MSAC consultation -
- Outcome Supported
Application details
Reason for application
Highly Specialised Therapy - National Health Reform Agreement.
Service or technology in this application
Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Type: Therapeutic technology
Medical condition this application addresses
Relapsed or refractory mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma.
Application documents
Application form
Consultation survey
Public summary document
Public summary document
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Meetings to consider this application
- PASC meeting: Expedited – bypassing PASC
- ESC meeting: 10 to 11 June 2021
- MSAC meeting:
- 29 to 30 July 2021
- 29 July 2023